【藥品性質提示】 ★LASA藥品：JAR01 Jardiance 錠劑 10mg (形似) 點擊看LASA藥品外觀比較圖

糖尿病 (SGLT2I / DPP4I) Diabetes mellitus, type 2
#仿單變更2021

Antidiabetic Agent, Dipeptidyl Peptidase 4 (DPP-4) Inhibitor; Antidiabetic Agent, Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor; Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor

See individual agents.

History of serious hypersensitivity (eg, anaphylaxis, angioedema, exfoliative skin conditions, urticaria, bronchial hyperreactivity<2021/8/13>) to empagliflozin, linagliptin, or any component of the formulation; severe renal impairment (eGFR <30 mL/minute/1.73 m2), ESRD, or dialysis

According to the manufacturer, use is not recommended during the second and third trimesters. Refer to individual monographs.

It is not known if empagliflozin or linagliptin are excreted in breast milk. Breastfeeding is not recommended by the manufacturer. Refer to individual monographs.

Genitourinary: Urinary tract infection (11% to 13%)
Endocrine & metabolic: Hypoglycemia (2% to 4%)
Respiratory: Upper respiratory tract infection (7%), nasopharyngitis (6% to 7%)
Postmarketing: Acute pancreatitis, ketoacidosis(使用前需考量病人易發生酮酸中毒之因素)<20210209>, hypotension due to intravascular volume depletion, increased amylase<2021/8/13>

Oral: Initial: Empagliflozin 10 mg/linagliptin 5 mg once daily; may increase to empagliflozin 25 mg/linagliptin 5 mg once daily

Safety and efficacy have not been established in pediatric patients

eGFR >30 mL/minute/1.73 m2: No dosage adjustment necessary.
eGFR <30 mL/minute/1.73 m2: Use is not recommended. Discontinue therapy when eGFR is persistently <30 mL/minute/1.73 m2.<20210209>
End-stage renal disease (ESRD) or dialysis: Use is contraindicated.

No dosage adjustment necessary.

Store at controlled room temperature, 25 degrees C (77 degrees F); excursions permitted between 15 and 30 degrees C (59 and 86 degrees F)Close lid tightly